Aldoxorubicin

DB06013InvestigationalSmall molecule

Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

Mechanism: INNO-206 is the (6-Maleimidocaproyl) hydrazone of doxorubicin. INNO-206 is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker. In preclinical models, INNO-206 was superior to doxorubicin with regard to antitumor efficacy and toxicity.
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors.Curator reviewed
Formula / weight: C₃₇H₄₂N₄O₁₃ · 750.758 g/mol (avg)
Code names: INNO-206

Resolves to

Compound

Structure

COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1

Targets

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

95Drug interactionsStructured to mechanism, not free text

22Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Aldoxorubicin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.